A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.

Key facts

Study ID
NCT05310071
Run by
Biogen
People needed
1027
Starts
2022-06-02
Expected to finish
2024-08-12
Last updated by the study team
2025-04-23

Who can join

Age: 60 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.